Baicalin attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2A receptor-induced SDF-1/CXCR4/PI3K/AKT signaling

Xiaoying Huang, Peiliang Wu, Feifei Huang, Min Xu, Mayun Chen, Kate Huang, Guo-ping Li, Manhuan Xu, Dan Yao and Liangxing Wang

Abstract

Background: Baicalin, an important flavonoid in Scutellaria baicalensis Georgi extracts, exerts a variety of pharmacological effects. In this study, we explored the effects of baicalin on chronic hypoxia-induced pulmonary arterial hypertension (PAH) and investigated the mechanism underlying these effects. Moreover, we examined whether the inflammatory response was mediated by the A2A receptor (A2AR) and stromal cell-derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4)-induced phosphatidylinositol-3-kinase (PI3K) signaling in vivo.

Methods: We established a hypoxia-induced pulmonary hypertension (HPH) mouse model by subjecting wild-type (WT) and A2AR knockout (A2AR−/−) animals to chronic hypoxia, and we examined the effects of a 4-week treatment with baicalin or the A2AR agonist CGS21680 in these animals. Invasive hemodynamic parameters, the right ventricular hypertrophy index, pulmonary congestion, the pulmonary arterial remodeling index, blood gas parameters, A2AR expression, and the expression of SDF-1/CXCR4/PI3K/protein kinase B (PKB; AKT) signaling components were measured.

Results: Compared with WT mice, A2AR−/− mice exhibited increased right ventricular systolic pressure (RVSP), right ventricle-to-left ventricle plus septum [RV/(LV + S)] ratio, RV weight-to-body weight (RV/BW) ratio, and lung wet weight-to-body weight (Lung/BW) ratio in the absence of an altered mean carotid arterial pressure (mCAP). These changes were accompanied by increases in pulmonary artery wall area and thickness and reductions in arterial oxygen pressure (P\text{O}_2) and hydrogen ion concentration (pH). In the HPH model, A2AR−/− mice displayed increased CXCR4, SDF-1, phospho-PI3K, and phospho-AKT expression compared with WT mice. Treating WT and A2AR−/− HPH mice with baicalin or CGS21680 attenuated the hypoxia-induced increases in RVSP, RV/(LV + S) and Lung/BW, as well as pulmonary arterial remodeling. Additionally, baicalin or CGS21680 alone could reverse the hypoxia-induced increases in CXCR4, SDF-1, phospho-PI3K, and phospho-AKT expression. Moreover, baicalin improved the hypoxemia induced by 4 weeks of hypoxia. Finally, we found that A2AR levels in WT lung tissue were enhanced by hypoxia and that baicalin up-regulated A2AR expression in WT hypoxic mice.

Conclusions: Baicalin exerts protective effects against clinical HPH, which are partly mediated through enhanced A2AR activity and down-regulated SDF-1/CXCR4-induced PI3K/AKT signaling. Therefore, the A2AR may be a promising target for baicalin in treating HPH.

Keywords: Baicalin, Pulmonary arterial hypertension, Receptor, Adenosine A2A, SDF-1, CXCR4
Background
Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disorder with a poor prognosis [1]. The disease is characterized by pulmonary vasoconstriction and increased pulmonary vascular resistance, which lead to right ventricular failure, fluid overload, and death [2]. The major histopathological features of PAH are vascular wall remodeling, in situ thrombosis, endothelial cell dysfunction and pulmonary artery smooth muscle cell (PASMC) proliferation [2, 3]. In Asian countries, PAH occurs in nearly 2 persons per 1,000,000 person-years, and PAH-related mortality occurs in 7 persons per 100 person-years [4]. However, the mechanism underlying the development of this disorder remains unknown. Increasing evidence suggests that treatments with anti-inflammatory effects, as well as treatments that can reverse cell proliferation, may be helpful for the management of PAH, but these approaches require further study.

Extracellular adenosine has anti-oxidant and anti-inflammatory properties and mediates a variety of physiological processes, including systemic vascular vasodilation and human pulmonary vessel regulation [5, 6]. The effects of adenosine are mediated by four cellular adenosine receptors: A1, A2A, A2B, and A3 [7]. Of these, the A2A receptor (A2A-R) is recognized as an important mediator of inflammatory and immune responses [8]. The A2A-R is activated by adenosine or agonists, such as CGS21680, and initiates negative-feedback mechanisms that inhibit systemic inflammatory responses [9]. The chemokine stromal cell-derived factor-1 (SDF-1), also named CXCL12, belongs to the C-X-C chemokine subfamily. SDF-1 exerts an effective function through binding to its specific receptor, CXCR chemokine receptor type 4 (CXCR4) [10]. The SDF-1/CXCR4 signaling system plays a crucial role in hematopoiesis, cardiogenesis, and vasculogenesis [11]. Specifically, the SDF-1/CXCR4 axis plays an important role in vascular remodeling. Recent evidence shows that inhibiting the SDF-1/CXCR4 axis attenuates hypoxia-induced PAH in neonatal mice by reversing pulmonary vascular cell proliferation [12]. Moreover, A2A-R activation reportedly suppresses chemokine receptor function via heterologous desensitization, thereby enhancing the anti-inflammatory effects of adenosine [13]. Therefore, we investigated whether A2A-R signaling affects the SDF-1/CXCR4 axis in PAH using A2A-R knockout (A2A-R−/−) mice. We hypothesized that A2A-R activation may have a beneficial effect on PAH by down-regulating the SDF-1/CXCR4 axis. SDF-1/CXCR4 signaling triggers cell proliferation and anti-apoptosis pathways, including the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB; AKT) and mitogen-activated protein kinase (MAPK/ERK) pathways [14]. PI3Ks are a subfamily of lipid kinases that regulate diverse cellular processes, including proliferation, growth and survival. AKT is a central and important downstream effector of PI3K and can be activated by PI3K [15, 16]. It is worth noting that PI3K/AKT signaling plays an important role in cell migration and proliferation [17]. More importantly, PI3K/AKT activation promotes smooth muscle cell proliferation, while PI3K/AKT inhibition attenuates hypoxia-induced PAH [18]. Therefore, PI3K/AKT signaling is an important pathway downstream of SDF-1/CXCR4 that participates in regulating homeostatic cell proliferation and inflammation.

Baicalin (7-glucuronic acid, 5,6-dihydroxy-flavone) is a major flavonoid component derived from Scutellaria baicalensis Georgi. Numerous studies have shown that baicalin exerts broad pharmacological effects, including anti-inflammatory, anti-oxidant, anti-thrombotic, anti-tumor and anti-proliferative effects [19]. Baicalin was recently shown to not only selectively bind to chemokine ligands but also mediate anti-inflammatory effects. In addition, baicalin was found to effectively eliminate lipopolysaccharide (LPS)-induced pulmonary edema and attenuate TXA2 mimetic (U46619)-induced PAH [20]. However, the potential therapeutic effects of baicalin in PAH have not yet been investigated systematically, and the mechanisms underlying these effects have not been well elucidated.

Thus, in the present study, we examined whether baicalin exerts protective effects against PAH via the A2A-R-induced SDF-1/CXCR4/PI3K/AKT signaling pathway in vivo. In addition, we explored the role of the A2A-R in a hypoxia-induced PAH model using A2A-R−/− mice.

Methods
Reagents
Baicalin was obtained from Sigma (purity>95%; St. Louis, MO, USA). The A2A-R agonist CGS21680 was obtained from Tocris (purity>98%; Bristol, UK). Rabbit antibodies against AKT (lot no. #4691), phospho-AKT (Ser-473, lot no. #4060), PI3K (lot no. #4257), phospho-PI3K (Tyr458, lot no. #4228), and GAPDH (lot no. #5174) were purchased from Cell Signaling Technology (Beverly, MA, USA). Mouse anti-A2A-R (lot no. ab115250) and rabbit anti-smooth muscle myosin heavy chain 11 (MYH11) (lot no. ab53219) were purchased from Abcam (Cambridge, UK). Rabbit anti-SDF-1 (lot no. sc-28,876) and anti-CXCR4 (lot no. NB100–74396) were purchased from Santa Cruz (CA, USA) and Novus Biologicals (Littleton, CO, USA), respectively. Horseradish peroxidase (HRP)-conjugated goat anti-rabbit (lot no. A0208) and anti-mouse (lot no. A0216) IgG were obtained from Beyotime (Haimen, China). SuperSignal (R) West Femto Maximum Sensitivity Substrate and a Bicinchoninic Acid (BCA) Protein Assay Kit were purchased from Pierce (Madison, WI, USA). Tetramethyl rhodamine-5-isothiocyanate (TRITC;
rhodamine)-conjugated goat anti-rabbit IgG (H&L) (lot no. ab6718) and fluorescein-5-isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (H&L) (lot no. ab6717) were obtained from Abcam (Cambridge, UK). A blood gas and electrolyte fluid pack was obtained from Radiometer (Copenhagen, Denmark).

**Animals**

A2AR-deficient (A2AR−/−) Balb/c mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA), and Balb/c mice were purchased from Slac Experimental Animal Technology (Shanghai, China). A2AR−/− and Balb/c WT mice were bred in our specific pathogen-free animal facility, maintained under a 12-h day-night cycle, allowed free access to food and water, and housed at a temperature and humidity of 22 ± 1 °C and 60 ± 5%, respectively. For our experiments, we used 12- to 14-week-old male A2AR−/− or Balb/c WT mice weighing 20–25 g. All experimental protocols were reviewed and approved by the Animal Ethics Committee of Wenzhou Medical University.

**Experimental protocols**

The mice were divided randomly into the following seven groups (10 mice per group): WT normoxia (saline-treated) [WT(S)]; WT hypoxia (saline-treated) [WTH(S)]; WT hypoxia-plus-baicilin (baicilin, 60 mg/kg i.p.) [WTH(+Bai)]; WT hypoxia-plus-CSG21680 (CGS21680, 0.25 mg/kg i.p.) [WTH(+CGS)]; A2AR−/−normoxia (saline-treated) [A2AR−/−(S)]; A2AR−/− hypoxia (saline-treated) [A2AR−/−H(S)]; and A2AR−/− hypoxia-plus-baicilin (baicilin, 60 mg/kg i.p.) [A2AR−/−H(+Bai)]. To establish a chronic hypoxia-induced PAH model, we subjected the mice to hypoxia for 28 days, as described by Huang et al. [21]. In brief, the mice in the WT(S) and A2AR−/−(S) groups were subjected to room air. The mice in the hypoxia groups were housed in a closed chamber (8 h per day), and the O2 concentration was dynamically maintained within a range from 9 to 11% by an automatic monitoring system.

**Invasive hemodynamic measurements**

To measure the right ventricular systolic pressure (RVSP) and the mean carotid arterial pressure (mCAP), we anesthetized the mice with 20% urethane (1 ml/100 g, i.p.). A homemade polyethylene (PE) catheter (inner diameter: 0.5 mm, outer diameter: 0.9 mm) was introduced into the right jugular vein and directed to the right ventricle (RV). Another catheter was inserted into the left carotid artery. The RVSP and mCAP were recorded and analyzed using a PowerLab system (PowerLab 8/35 Multi-channel Biological Signal Recording System, AD Instruments, Colorado Springs, Australia).

**Right ventricular hypertrophy and pulmonary congestion measurements**

At the end of the hemodynamic measurement period, the hearts and lungs were removed from the animals. The hearts were then divided into the RV, left ventricle (LV), and septum (S). The RV-to-(LV + S) [RV/(LV + S)] and RV-to-body weight (RV/BW) ratios were calculated as indices reflecting right ventricular hypertrophy. Additionally, the lung wet weight-to-body weight (Lung/BW) ratio was calculated to assess pulmonary congestion.

**Pulmonary arterial remodeling measurement**

Lung tissue specimens obtained from the above mice were chopped into several pieces, fixed in 4% paraformaldehyde for 24 h at 4 °C, dehydrated, embedded in paraffin, and cut into 4-μm thick sections before being stained with hematoxylin-eosin (HE). The pulmonary arteries (with external diameters of 50–100 μm) were randomly selected and analyzed using Image-Pro Plus 6.0 software (Media Cybernetics, USA), and the ratios of pulmonary artery wall area to total area (WA/TA) and wall thickness to total thickness (WT/TT) were calculated to evaluate pulmonary arterial remodeling.

**Arterial blood gas analysis**

On day 28 of hypoxia, the mice were anesthetized with 20% urethane. Arterial blood samples (0.5–1.0 ml) were collected from the left carotid artery using a homemade PE catheter (inner diameter: 0.5 mm, outer diameter: 0.9 mm) syringe. The blood samples were tested using an ABL90 FLEX blood gas analyzer (Radiometer, Denmark). Specifically, the hydrogen ion concentration (pH) and arterial oxygen tension (PaO2) were measured.

**Immunofluorescence detection of SDF-1 and CXCR4 protein expression in pulmonary arterioles**

To assess SDF-1 and CXCR4 expression in the treated animals, we fixed the upper lobe of the right lung with 4% paraformaldehyde for 48 h, placed the lung tissues in a graded sucrose series and embedded them with Tissue-Tek OCT compound (Sakura, Japan). The 10-μm-thick sections were then fixed with ice-cold methanol for 10 min and blocked with 5% bovine serum albumin for 30 min at 37 °C before being incubated with anti-smooth muscle MYH11 antibody (1:100) overnight at 4 °C. The sections were then washed and incubated with FITC-conjugated goat anti-rabbit IgG antibody (1:500) for 1 h at room temperature before being washed 3 times with phosphate-buffered saline (PBS) and incubated with specific primary rabbit antibodies against SDF-1 and CXCR4 (1:50) overnight at 4 °C. After being washed in PBS, the sections were incubated for 1 h at room temperature with TRITC-conjugated goat anti-rabbit IgG antibody (1:500). The immunolabeled
sections were observed using a Nikon Eclipse Ti microscope, and the fluorescence intensity was analyzed using Image-Pro Plus 6.0 software (Media Cybernetics, USA).

**Immunohistochemical detection of A2AR expression in pulmonary arterioles**

The fixed lower lobes of the right lungs were removed from 4% paraformaldehyde after 24 h. To determine A2AR expression, we incubated the 10-μm-thick paraffin sections of lung tissue with anti-A2AR antibody, diluted 1:200; after an overnight incubation at 4 °C, the sections were washed three times with PBS and incubated for 1 h with HRP-conjugated goat anti-mouse IgG diluted 1:100. The sections were subsequently observed under the Nikon microscope, and the positively stained areas of the lung sections were identified using Image-Pro Plus 6.0 software (Media Cybernetics, USA).

**Western blot detection of A2AR, SDF-1, CXCR4, PI3K and AKT expression in lung homogenates**

Frozen lung tissue specimens were homogenized with an automatic tissue lysing system (MP, USA), sonicated three times, and centrifuged at 12,000 rpm for 30 min at 4 °C. The supernatant was collected at 4 °C, and the protein concentration in the supernatant was subsequently determined using a BCA Protein Assay Kit (Thermo, USA). The proteins were then electrotransferred to PVDF membranes (Millipore, USA), which were blocked in 5% nonfat milk in PBS for 1 h at room temperature. The membranes were subsequently incubated with specific primary antibodies against A2AR (1:1000), SDF-1 (1:500), CXCR4 (1:1000), AKT (1:1000), phospho-AKT (1:500), PI3K (1:1000), phospho-PI3K (1:500), and GAPDH (1:1000) overnight at 4 °C before being incubated with a 1:10,000 dilution of HRP-conjugated goat anti-rabbit or anti-mouse IgG for 1 h. The membranes were visualized using a SuperSignal enhanced chemiluminescence (ECL) substrate (Pierce, USA), and then analyzed using Quantity One v 4.6.2 software (BioRad Laboratories, USA).

**Statistical analysis**

All values are expressed as the mean ± standard deviation (SD). Comparisons between 2 groups were analyzed by Student’s t-test, and multiple comparisons were analyzed by one-way analysis of variance using the least significant difference test (equal variances assumed) or Tamhane’s test (equal variances not assumed). All statistical analyses were performed using SPSS version 21.0 (IBM, Somers, NY, USA). P < 0.05 was considered statistically significant.

**Results**

**The A2AR and baicalin alleviated hypoxia-induced hemodynamic changes**

As shown in Fig. 1a, RVSP was much higher in hypoxic WT and A2AR−/− mice than in normoxic WT and A2AR−/− mice. However, this increase in RVSP was inhibited by baicalin or CGS21680 treatment in both WT and A2AR−/− mice. Similarly, RVSP was significantly higher in A2AR−/−(S), A2AR−/−H(S), and A2AR−/−H(Bai) mice than in WT(S), WTH(S), and WTH(Bai) mice, (P < 0.05, P < 0.01, and P < 0.01, respectively). However, there were no significant differences in mCAP among the 7 experimental groups (Fig. 1b). The A2AR and baicalin alleviated hypoxia-induced right ventricular hypertrophy and pulmonary congestion

To investigate the effects of hypoxia on PAH in WT and A2AR−/− mice, we measured the RV/(LV + S), RV/BW and Lung/BW ratios after 28 days of hypoxia and found that all of these parameters were increased in WT and A2AR−/− mice. Repeated administration of baicalin (60 mg/kg/day, i.p. from day 0 to 28) significantly reduced the RV/(LV + S) and RV/BW ratios in both WT and A2AR−/− mice without changing the Lung/BW ratio. Repeated administration of CGS21680 (0.25 mg/kg/day, i.p. from day 0 to 28) also significantly reduced the RV/(LV + S), RV/BW, and Lung/BW ratios in WT mice compared with those in WTH(S) and WTH(Bai) mice. Additionally, the RV/(LV + S), RV/BW, and Lung/BW ratios were greater in the A2AR−/−(S), A2AR−/−H(S), and A2AR−/−H(Bai) groups than in the WT(S), WTH(S), and WTH(Bai) groups (Fig. 2a–c).

The A2AR and baicalin alleviated hypoxia-induced pulmonary arterial remodeling and morphological changes

To determine the effects of the A2AR and baicalin on pulmonary arterial remodeling, we investigated the pulmonary artery wall area to total area (WA/TA%) and wall thickness to total thickness (WT/TT%) by HE staining. The pulmonary artery WA/TA% and WT/TT% ratios were significantly greater in the PAH model groups compared with the control groups, i.e., the WT(S) and A2AR−/−(S) groups. While these increases were reversed by both baicalin and CGS21680 treatment, CGS21680 exerted a stronger inhibitory effect. Additionally, the pulmonary artery WA/TA% and WT/TT% ratios were significantly greater in the A2AR−/−(S) and A2AR−/−H(Bai) groups than in the WT(S) and WTH(Bai) groups. However, there were no significant differences in the pulmonary artery WA/TA% and WT/TT% ratios between the WTH(S) and A2AR−/−H(S) groups (Fig. 3a, b, and c).
Normalizing effect of the A\textsubscript{2AR} and baicalin on arterial blood gas variables in the hypoxia-induced PAH mouse model

After 4 weeks, a marked decrease in P\textsubscript{aO\textsubscript{2}} was observed in mice subjected to chronic hypoxia compared with mice subjected to normoxia, indicating that the former mouse group had hypoxemia. Repeated administration of baicalin and CGS21680 significantly inhibited the decrease in P\textsubscript{aO\textsubscript{2}} without affecting pH. P\textsubscript{aO\textsubscript{2}} was significantly higher in the WTH(S) group than in the A\textsubscript{2AR}\textsuperscript{−/−} H(S) group (P < 0.05), and pH was significantly higher in the WT(S) and WTH(Bai) groups than in the A\textsubscript{2AR}\textsuperscript{−/−} (S) and A\textsubscript{2AR}\textsuperscript{−/−} H(Bai) groups (P < 0.01) (Fig. 4a, b).
The A2AR and baicalin attenuated increases in CXCR4 expression in the hypoxia-induced PAH mouse model

To investigate the link between inflammation and the response to chronic hypoxia, we measured the effects of the A2AR and baicalin on CXCR4 expression in lung tissues by immunofluorescence and western blot. We performed immunofluorescence on CXCR4 and MYH11 (a marker of PASMCs). As shown in Fig. 5a and b, CXCR4 expression was significantly up-regulated in the pulmonary artery tissues of the hypoxia groups compared with the pulmonary artery tissues of the control groups. The abovementioned hypoxia-induced increases in CXCR4 expression were inhibited in the baicalin and CGS21680 treatment groups. Furthermore, the CXCR4 fluorescence intensity ratio was greater in the A2AR−/−(S), A2AR−/−H(S) groups than in the WT(S), WTH(S) mice (P < 0.05, P < 0.05, respectively); however, there was no difference in the CXCR4 ratio between the WTH(Bai) and A2AR−/−H(Bai) groups. Western blot analysis of the total lung homogenates from the WT and A2AR−/− groups showed that hypoxia increased CXCR4 expression. Consistent with these findings, we found that treating PAH mice with baicalin or CGS21680 abolished hypoxia-induced SDF-1 expression. Similarly, there were no significant differences in the relative fluorescence intensity of SDF-1 between the WT(S), WTH(S), and WTH(Bai) and the A2AR−/−(S), A2AR−/−H(S), and A2AR−/−H(Bai) groups; however, compared with the WT groups, the A2AR−/− groups exhibited slightly increased SDF-1 expression (Fig. 6a, b).

The A2AR and baicalin attenuated PI3K phosphorylation and AKT phosphorylation activation in the hypoxia-induced PAH mouse model

Our results showed that phospho-PI3K and phospho-AKT levels were higher in the WT hypoxia group than in the WT normoxia group. Baicalin significantly reduced the phospho-PI3K and phospho-AKT protein levels in hypoxic mice and exerted similar effects on the phospho-PI3K and phospho-AKT protein levels in A2AR−/− mice. The A2AR agonist CGS21680 served as a positive control and decreased the phospho-PI3K and phospho-AKT protein levels in the lung tissues of the abovementioned mice to an even greater extent than did baicalin. Additionally, there were significant differences in the phospho-PI3K and phospho-AKT levels between the WT(S), WTH(S), and WTH(Bai) groups and the
A2AR expression in the hypoxia-induced PAH mouse model, we assessed the effects of baicalin (+Bai, 60 mg/kg/day) and CGS21680 (+CGS, 0.25 mg/kg/day) on the WT/TT (%) (a; n = 8), WA/TA (%) (b; n = 8) reversal in WT and A2AR−/− mice. Representative images showing hypoxia-induced remodeling in the pulmonary arteries of mice in the WT and A2AR−/− groups (c) (×400; scale bars indicate 50 μm). Data are presented as the mean ± SD. **Value significantly greater than the corresponding value in saline-treated normoxic mice (**P < 0.05, ***P < 0.01). *Value significantly less than the corresponding value in mice subjected to 4 weeks of hypoxia (*P < 0.05, **P < 0.01). +Value significantly greater than the corresponding value in WT saline-treated mice and WT baicalin-treated mice (+P < 0.05). WTH, wild-type hypoxic; A2AR−/−H, A2AR−/− hypoxic; s, saline-treated

**Discussion**

In our study, baicalin or CGS21680 can attenuate chronic hypoxia induced increasing in RV/LV + S, RV/BW, RVSP, Lung/BW, and thickening of pulmonary arteriole in mice. Simultaneously, baicalin can significantly attenuate histopathological appearance induced by chronic hypoxia. Furthermore, the major finding of the present study is that the protective effect of baicalin was dependent on A2AR-related, SDF-1/CXCR4-induced PI3K/AKT signaling, as demonstrated in vivo.

PAH is a progressive and fatal disorder with a poor prognosis, and drugs that can effectively treat the disease remain lacking. HPH is characterized by continuous increases in pulmonary artery pressure, pulmonary vascular
resistance and pulmonary vascular remodeling [22]. The pathology of HPH is complex. It is thought that inflammation and smooth muscle cell proliferation may play key roles in the disease. The chronic hypoxia-induced PAH mouse model has been widely used for studying pulmonary hypertension, which is characterized by increased pulmonary arterial pressure, vascular remodeling, and RV hypertrophy [21]. We successfully established a model of hypoxia-induced PAH, as demonstrated by the observed increases in RV/LV + S, RV/BW, RVSP, Lung/BW and pulmonary arteriolar thickening with luminal stenosis. Recent studies have shown that inflammation appears to play an important role in HPH. Specifically, studies have demonstrated that inflammatory cells (including macrophages, lymphocytes, neutrophils, and mast cells) and certain chemokines are closely related to the development of cell proliferation and vascular remodeling, and RV hypertrophy [21]. It is noteworthy that there was no significant difference in pulmonary artery SDF-1 expression between the A2AR−/−(S), A2AR−/−H(S), and A2AR−/−H(Bai) groups and the WT(S), WTH(S), and WTH(Bai) groups, as demonstrated by immunofluorescence; however, SDF-1 expression in the lung homogenates was significantly higher in the A2AR−/− groups than in the WT groups, as demonstrated by western blot. We surmised that there are two probable reasons for these findings. First, lung tissue homogenates contain not only pulmonary arteries but also pulmonary veins, alveoli, and bronchi. Second, in pulmonary hypertension, inflammatory factors act not only on pulmonary arteries but also on adjacent lung tissue. Therefore, SDF-1 levels in the lung homogenates may better reflect lung tissue inflammation than other parameters. These reasons might also account for the CXCR4 levels observed in the pulmonary artery and lung homogenates. CXCR4 is a seven-span transmembrane G-protein-coupled receptors, indicating that CXCR4 selectively binds SDF-1 to mediate intracellular signaling through the heterotrimeric G protein, which consists of three subunits: Gα, Gβ, and Gγ. In addition, the Gα subunit family is currently divided into four classes, Gαs, Gai, Gαq, and Gα12. Meanwhile, the Gai subunit is acting as a connecting bridge between SDF-1/CXCR4 axis and PI3K/AKT pathway [26]. Upon ligand binding to the CXCR4, the Gα monomer triggers PI3K/AKT-pathway activation [10]. SDF-1/CXCR4 signaling affects cell cycle progression and cell proliferation via the ERK and PI3K/AKT pathways [27], and PI3K/AKT signaling plays an essential role in regulating cell cycle progression and cell proliferation.
migration, proliferation, and survival [17]. Excessive cell proliferation is a key factor of pulmonary vascular remodeling. Notably, recent studies indicate that PI3K/AKT activation by SDF-1/CXCR4 has a major impact on cell migration and proliferation [28, 29]. Consistent with these studies, we noted that PI3K/AKT signaling was elevated in the lungs of hypoxic mice; this finding is supported by our observation of elevated phospho-PI3K and phospho-AKT levels in hypoxic mice. The abovementioned results are consistent with those pertaining to SDF-1/CXCR4 activation. However, the specific mechanism linking SDF-1/CXCR4 signaling to PI3K/AKT signaling remains unclear and requires further investigation.

Adenosine is an endogenous vasodilator, and the binding of extracellular adenosine to its receptors (A1R, A2AR, A2BR, and A3R) is known to have multiple physiological effects [7]. Saadjian et al. found that adenosine plasma levels were down-regulated in patients with PAH [30]; however, in our study, A2AR

**Fig. 5** The A2AR and baicalin attenuated CXCR4 expression in the hypoxia-induced PAH mouse model. CXCR4 and MYH11 expression levels in mouse PASMCs were analyzed by immunofluorescence staining (a, n = 3). CXCR4 protein is stained red, and MYH11 is stained green to indicate the PASMCs (×400; scale bars indicate 50 μm). CXCR4 fluorescence intensity was calculated (b, n = 3). CXCR4 protein expression levels in lung tissue were examined by western blot. GAPDH served as an internal control (c, d, n = 3). Data are presented as the mean ± SD. *Value significantly greater than the corresponding value in saline-treated normoxic mice (##P < 0.01). **Value significantly less than the corresponding value in hypoxic mice (**P < 0.05, ***P < 0.01). §Value significantly less than the corresponding value in baicalin-treated mice (§P < 0.05, §§P < 0.01). †Value significantly different between WT and A2AR−/− mice (†P < 0.05, ††P < 0.01). WTH, wild-type hypoxic; A2AR−/−H, A2AR−/− hypoxic; s, saline-treated.
expression was up-regulated in the lung tissues of hypoxic mice, suggesting the presence of a negative feedback loop between adenosine and the A2AR may exist in PAH. Therefore, we plan elucidate the relationship between adenosine and the A2AR in the future. Xu et al. found that A2AR−/− mice are more susceptible to developing PAH than other mice, indicating that this receptor exerts protective effects against PAH development [31]. In our research, A2AR−/− mice exhibited more severe right ventricular hypertrophy and pulmonary arterial remodeling than did WT mice, suggesting that the A2AR plays an important role in PAH development. In addition, our understanding of the protective role played by the A2AR in PAH is superior to our understanding of the relationship between the A2AR and the SDF-1/CXCR4-PI3K/AKT pathway in PAH. In this study, we obtained the first evidence that SDF-1/CXCR4 and phospho-PI3K/phospho-AKT protein expression levels are significantly greater in A2AR−/− mice than in WT mice, demonstrating that the A2AR can down-regulate the SDF-1/CXCR4-PI3K/AKT pathway in PAH.
Baicalin is a flavonoid component isolated from the flowering plant *Scutellaria baicalensis* Georgi. A recent study demonstrated that baicalin can effectively attenuate vascular smooth muscle cell proliferation by blocking the ERK1/2 signaling pathway [32]. Our previous study showed that baicalin can up-regulate ADAMTS-1 expression in chronic hypoxia to inhibit collagen I synthesis, thereby contributing to the attenuation of pulmonary hypertension and pulmonary vessel remodeling [33]. Baicalin can reportedly inhibit the expression of inflammatory factors in rats with acute pancreatitis [34]. However, whether baicalin can inhibit SDF-1/CXCR4 activity via the A$_2$AR in HPH remains unclear. The abovementioned factors and pathways play crucial roles in the initiation of vascular remodeling. The present study showed that baicalin was effective in reducing RVSP, right ventricular hypertrophy, SDF-1/CXCR4 expression and PI3K/AKT pathway activation in PAH, thereby partially reversing pulmonary vascular remodeling. These results indicate that the interactions of baicalin with the abovementioned factors and pathways might be crucial mechanisms through which baicalin protects mice with HPH. Moreover, baicalin and CGS 21680 (an A$_2$AR agonist) significantly elevated A$_2$AR expression. These data indicate that baicalin exerts protective effects against HPH through the A$_2$AR.

Regarding the results of our arterial blood gas analysis, we demonstrated that the PaO$_2$ (hypoxemia) and pH values were significantly decreased in mice subjected to chronic hypoxia. Our results also demonstrated that baicalin and CGS21680 (an A$_2$AR agonist) significantly elevated A$_2$AR expression. These data indicate that baicalin exerts protective effects against HPH through the A$_2$AR.

![Fig. 7](image)

The A$_2$AR and baicalin attenuated PI3K phosphorylation and AKT phosphorylation in the hypoxia-induced PAH mouse model. Phospho-PI3K levels and PI3K protein expression levels in lung tissues were examined by western blot. GAPDH served as an internal control (a, b; n = 3). Phospho-AKT levels and AKT protein expression levels in lung tissues were examined by western blot. GAPDH served as an internal control (c, d; n = 3). Data are presented as the mean ± SD. *Value significantly greater than the corresponding value in saline-treated normoxic mice (\(^*P < 0.05,\)**\(^*P < 0.01\)). **Value significantly less than the corresponding value in hypoxic mice (\(^*P < 0.05,\)**\(^**P < 0.01\)). §Value significantly less than the corresponding value in baicalin-treated mice (\(^*P < 0.01\)). #Value significantly greater than the corresponding value in WT saline-treated mice, WT hypoxic mice, WT baicalin-treated mice (\(^*P < 0.05,\)**\(^**P < 0.01\)). WTH, wild-type hypoxic; A$_2$AR$^{-/-}$H, A$_2$AR$^{-/-}$ hypoxic; s, saline-treated.
and to clarify the differences in arterial blood gas variables between WT and A2AR−/− mice.

Conclusions
Baicalin attenuates pulmonary arterial pressure, pulmonary vascular remodeling, and right ventricular hypertrophy in mice exhibiting HPH. Baicalin exerts protective effects against clinical HPH, and these effects are mediated in part through enhanced A2AR activity and down-regulated SDF-1/CXCR4-induced PI3K/AKT signaling (Fig. 9). Therefore, the A2AR might be a promising target for baicalin in the treatment of HPH.

Fig. 8 Baicalin increased A2AR expression in the hypoxia-induced PAH mouse model. A2AR protein expression levels in the pulmonary arteries were examined by immunochemical analysis with an anti-A2AR antibody (a, n = 10) (×400; scale bars indicate 50 μm). The mean A2AR density was calculated (b, n = 10). A2AR protein expression levels in lung tissues were examined by western blot. GAPDH served as an internal control (c, d, n = 3). Data are presented as the mean ± SD. *Value significantly greater than the corresponding value in saline-treated normoxic mice (*P < 0.05, **P < 0.01). Value significantly greater than the corresponding value in hypoxic mice (†P < 0.05, ††P < 0.01). §Value significantly greater than the corresponding value in baicalin-treated mice (§P < 0.05, §§P < 0.01). WTH, wildtype hypoxic; s, saline-treated

Fig. 9 The A2AR and baicalin attenuated hypoxia-induced PAH. Baicalin protects against hypoxia-induced PAH in part by enhancing A2AR expression and then down-regulating the SDF-1/CXCR4-induced PI3K/AKT signaling pathway.
Abbreviations
A2AR: A2A receptor; A2AR−/−: A2AR knockout; BW: body weight; CXCR4: C-X-C chemokine receptor type 4; HE: hematoxylin-eosin; HPh: hypoxia-induced pulmonary hypertension; LV: left ventricle; mCAP: mean carotid arterial pressure; MYH11: smooth muscle myosin heavy chain 11; PAH: pulmonary arterial hypertension; PAO2: arterial oxygen pressure; PASMC: pulmonary artery smooth muscle cell; pH2: hydrogen ion concentration; PI3K: phosphatidylinositol-3-kinase; RV: right ventricle; RVSP: right ventricular systolic pressure; S: septum; SDF-1: stromal cell-derived factor-1; TA: total area; TI: total thickness; WA: wall area; WT: wall thickness; WL: wild-type

Acknowledgements
Not applicable.

Funding
This study was supported by the Chinese National Natural Science Foundation (grant nos. 81,270,110, 81,473,406 and 81,470,250), the Natural Science Foundation of Zhejiang Province (grant no. Y17H010028), and the Project of the Health Department of Zhejiang Province of China (grant nos. 2016DA005 and 2012DDA033).

Availability of data and materials
All relevant data and materials are stored at the Key Laboratory of Heart and Lung of Wenzhou Medical University and can be obtained from the first author and corresponding author.

Authors' contributions
XYH and PLW designed the experiments and drafted the manuscript. PLW, FFH, MX, and KTH performed the experiments. MYC, DY and GPL participated in the statistical analyses. LXW and MHX helped draft the manuscript. LXW participated in the study design and coordinated the research groups; all authors read and approved the final manuscript.

Ethics approval
All experimental protocols conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and were approved by the Animal Ethics Committee of Wenzhou Medical University. Additionally, all animals were handled with care and euthanized humanely during the study.

Consent for publication
All authors of this paper consent to publication of the work.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Division of Pulmonary Medicine, The First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Heart and Lung, Wenzhou, Zhejiang 325000, People’s Republic of China. 2Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, People’s Republic of China. 3Department of Respiratory Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310013, People’s Republic of China. 4Wenzhou Medical University, Wenzhou, Zhejiang 325000, People’s Republic of China.

Received: 28 March 2017 Accepted: 28 July 2017
Published online: 03 August 2017

References
1. Park YM, Chung WJ, Choi DY, Baek HJ, Jung SH, Choi IS, Shin BK. Functional class and targeted therapy are related to the survival in patients with pulmonary arterial hypertension. Yonsei Med J. 2014;55:1526–32.
2. Farber HW, Lysalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655–65.
3. Zhao YD, Peng J, Grante E, Lin K, Lu C, Wu L, Machua T, Waddell TK, Keshayee S, de Perrot M. Pulmonary vascular changes 22 years after single lung transplantation for pulmonary arterial hypertension: a case report with molecular and pathological analysis. Pulm Circ. 2015;5:739–43.
4. Chung WJ, Park YB, Jeon CH, Jung JW, Ko KP, Choi SJ, Lee HS, Lee JS, Jung HO, Investigators K. Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension. J Korean Med Sci. 2015;30:1429–38.
5. Salleh A, Elsherbiny NM, Ibrahim AS, Liou GI, Chaddi A, Al-Shabrawey M, Elmarabyy AA. Adenosine kinase inhibition protects the kidney against streptozotocin-induced diabetes through anti-inflammatory and anti-oxidant mechanisms. Pharmaco. 2014;85:45–54.
6. Constein BN, Sittkovsky M. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13:541–51.
7. Safarzadeh E, Jadidi-Niaragh F, Motalebnezhad M, Yousefi M. The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis. Inflamm Res. 2016;65:11–20.
8. Andres RM, Terencio MC, Arau J, Paya M, Valcuenve-Caver F, Navalon P, Montesinos MC. Adenosine A2A and A2B Receptors Differentially Modulate Keratinocyte Proliferation: Possible Deregression in Psoriatic Epidermis. J Invest Dermatol. 2017;137:123–31.
9. Ohla A, Sittkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 20014;419:16–20.
10. Doring Y, Pawi L, Weber C, Noels H. The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol. 2014;5:212.
11. Juarez J, Bendall L, Bradstock K. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Des. 2004;10:1245–59.
12. Young KC, Torres E, Hatizetegos KE, Hehre D, Sugulahra C, Hare JM. Inhibition of the SDF-1/CXCR4 axis attenuates neonatal hypoxia-induced pulmonary hypertension. Circ Res. 2009;104:293–301.
13. Zhang N, Yang D, Dong H, Chen Q, Dimitrova D, Rogers TJ, Sittkovsky M, Oppenjem JJ. Adenosine A2A receptors induce heterologous desensitization of chemokine receptors. Blood. 2006;108:38–44.
14. Chen J, Chen J, Chen S, Zhang C, Zhang L, Xiao X, Das A, Zhao Y, Yuan B, Morris M, et al. Transfusion of CXCR4-primed endothelial progenitor cells reduces cerebral ischemic damage and promotes repair in db/db diabetic mice. PLoS One. 2012;7:e50105.
15. Du L, Hao M, L C, Wu W, Wang W, Ma Z, Yang T, Zhang N, Isaac AT, Zhu X, et al. Quercetin inhibited epithelial mesenchymal transition in diabetic rats, high-glucose-cultured lens, and SHR01/04 cells through transforming growth factor-beta2/phosphoinositol-3 kinase/Akt pathway. Mol Cell Endocrinol. 2017;452:44–56.
16. Akinleye A, Avvaru P, Furgan S, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6:88.
17. Wei L, Zhang B, Cao W, Xing Y, Yu X, Zhu D. Inhibition of CXCL12/CXCR4 suppresses pulmonary arterial smooth muscle cell proliferation and cell cycle progression via PI3K/Akt pathway under hypoxia. J Recept Signal Transduct Res. 2015;35:329–39.
18. Garat CV, Crossno JT Jr, Sullivan TM, Reusch JE, Klemm DJ. Inhibition of phosphatidylinositol 3-kinase/Akt signaling attenuates hypoxia-induced pulmonary artery remodeling and suppresses CREB depletion in arterial smooth muscle cells. J Cardiovasc Pharmacol. 2013;62:539–48.
19. Gare BP, Moon SK, Kim H. Scutellaria baikalensis in stroke management: nature's blessing in traditional Eastern medicine. Chin J Integr Med. 2014;20:712–20.
20. Tsai HH, Chen U, Lo YC. Effects of San-Huang-Xie-Xin-Tang on U64619-induced increase in pulmonary arterial blood pressure. J Ethnopharmacol. 2008;117:457–62.
21. Huang X, Zou R, Yu X, Chen M, Guo Q, Ral H, Yao D, Xu X, Chen Y, Ding C, et al. Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2A receptor related mitrochondia-dependent apoptosis pathway. J Mol Cell Cardiol. 2015;82:153–66.
22. Cogolludo A, Moreno L, Villamar E. Mechanisms controlling vascular tone in pulmonary arterial hypertension: implications for vasodilator therapy. Pharmacology. 2007;79:65–75.
23. Crosswhite P, Sun Z. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens. 2010;28:201–12.
24. Kucia M, Jankowski K, Reca R, Wyczynski M, Bardusa L, Allendorf DJ, Zhang J, Ratajczak J, Ratajczak MZ. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 2004;35:233–45.
25. Shu HK, Yoon Y, Hong S, Xu K, Gao H, Hao C, Torres Gonzalez E, Nayra C, Rojas M, Shim H. Inhibition of the CXCL12/CXCR4 axis as preventive therapy for radiation-induced pulmonary fibrosis. PLoS One. 2013;8:e79788.
26. Pawig L, Klasen C, Weber C, Bernhagen J, Noels H. Diversity and Interconnections in the CXCR4 Chemokine Receptor/Ligand Family: Molecular Perspectives. Front Immunol. 2015;6:429.

27. Yang P, Wang Q, Huo H, Li Q, Zhao Y, Liu Y. SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial-mesenchymal transition via ERK and PI3K/Akt pathway. Med Oncol. 2015;32:377.

28. Wu M, Chen Q, Li D, Li X, Li X, Huang C, Tang Y, Zhou Y, Wang D, Tang K, et al. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways. J Cell Biochem. 2008;103:245–55.

29. Yu J, Li M, Ou Z, Yan D, Li D, Ruan Q. SDF-1/CXCR4-mediated migration of transplanted bone marrow stromal cells toward areas of heart myocardial infarction through activation of PI3K/Akt. J Cardiovasc Pharmacol. 2010;55:496–505.

30. Saadjian AY, Paganelli F, Gaubert ML, Levy S, Guieu RP. Adenosine plasma concentration in pulmonary hypertension. Cardiovasc. Res. 1999;43:228–36.

31. Xu MH, Gong YS, Su MS, Dai ZY, Dai SS, Bao SZ, Li N, Zheng RY, He JC, Chen JF, Wang XT. Absence of the adenosine A2A receptor confers pulmonary arterial hypertension and increased pulmonary vascular remodeling in mice. J Vasc Res. 2011;48:171–83.

32. Dong LH, Wen JK, Mao SB, Jia Z, Hu HJ, Sun RH, Wu Y, Han M. Baicalin inhibits PDGF-BB-stimulated vascular smooth muscle cell proliferation through suppressing PDGFRbeta-ERK signaling and increase in p27 accumulation and prevents injury-induced neointimal hyperplasia. Cell Res. 2010;20:1252–62.

33. Liu P, Yan S, Chen M, Chen A, Yao D, Xu X, Cai X, Wang L, Huang X. Effects of baicalin on collagen I and collagen III expression in pulmonary arteries of rats with hypoxic pulmonary hypertension. Int J Mol Med. 2015;35:901–8.

34. Zhang X, Tian H, Wu C, Ye Q, Jiang X, Chen L, Cai Y, Xu P, Yuan W. Effect of baicalin on inflammatory mediator levels and microcirculation disturbance in rats with severe acute pancreatitis. Pancreas. 2009;38:732–8.